Extended trial tests new injection for rare muscle diseases
NCT ID NCT04628936
Summary
This study followed patients with polymyositis or dermatomyositis who had previously participated in a related trial. It aimed to assess the long-term safety and effectiveness of weekly KZR-616 injections over up to 96 weeks of treatment. The goal was to see if the drug could help control these chronic autoimmune diseases that cause muscle weakness and inflammation.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DERMATOMYOSITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
KZR Research Site
Beverly Hills, California, 90211, United States
-
KZR Research Site
Orange, California, 92868, United States
-
KZR Research Site
Miami, Florida, 33136, United States
-
KZR Research Site
Kansas City, Kansas, 66160, United States
-
KZR Research Site
Baltimore, Maryland, 21224, United States
-
KZR Research Site
Ann Arbor, Michigan, 48109, United States
-
KZR Research Site
Duncansville, Pennsylvania, 16635, United States
-
KZR Research Site
Pittsburgh, Pennsylvania, 15213, United States
-
KZR Research Site
Austin, Texas, 78756, United States
-
KZR Research Site
Prague, Czechia
Conditions
Explore the condition pages connected to this study.